Multiple tumor-associated antigens and T-cell surface glycoprotein CD3 epsilon chain (Multi-TAA/CD3E)

This target profile represents a therapeutic strategy involving the simultaneous engagement of one or more tumor-associated antigens (TAAs) and the T-cell surface glycoprotein CD3 epsilon chain. By cross-linking T cells to malignant cells, these multi-specific agents bypass the need for traditional major histocompatibility complex (MHC) class I recognition, allowing for the potent activation of cytotoxic T lymphocytes against tumor cells [Nature Reviews Cancer, 2023]. This approach is widely utilized in the development of bispecific T-cell engagers (BiTEs) and other multi-specific antibody formats [Immunology & Cell Biology, 2015]. The biological consequence of this interaction is the formation of an immunological synapse, leading to the release of cytotoxic granules such as perforin and granzymes, which induce apoptosis in the target cell [Nature Reviews Drug Discovery, 2020]. Clinically, this strategy has proven highly effective in hematologic malignancies, with several approved drugs targeting antigens like CD19, CD20, and BCMA [FDA, 2014; FDA, 2022]. However, the potent systemic activation of T cells can lead to significant adverse events, most notably cytokine release syndrome (CRS) and neurotoxicity [Lee et al., 2019]. Ongoing research aims to expand this modality into solid tumors by identifying more selective TAAs and optimizing the affinity of the CD3-binding domain to improve the therapeutic window [Journal of Hematology & Oncology, 2021].

Other names

Bispecific T-cell engager targetBiTE targetT-cell redirecting targetCD3-redirecting multi-specific targetTAA/CD3 complex

The mechanism involves the simultaneous engagement of one or more tumor-associated antigens (TAAs) on a cancer cell and the CD3 epsilon subunit of the T-cell receptor complex on a T-cell. This dual binding facilitates the formation of an immunological synapse, leading to MHC-independent T-cell activation and the subsequent release of cytotoxic granules (perforin and granzymes) that induce apoptosis in the target tumor cell [Nature Reviews Cancer, 2023; Immunology & Cell Biology, 2015].